4-氨基甲基-1-甲基-哌啶-4-基胺 | 125889-78-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-氨基甲基-1-甲基-哌啶-4-基胺
• 英文名称: 4-aminomethyl-1-methyl-piperidin-4-ylamine
• 英文别名: 4-amino-4-aminomethyl-1-methylpiperidine；4-(aminomethyl)-1-methylpiperidin-4-amine
• CAS: 125889-78-3
• 化学式: C₇H₁₇N₃
• 分子量: 143.232
• InChiKey: CGFRCBQIPHFZJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氨基甲基-1-甲基-哌啶-4-基胺 、 3-bromorifamycin S 在 potassium hexacyanoferrate(III) 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以2.4%的产率得到spiro[N-methyl-piperidine-3,4-piperazinorifamycin S]
  参考文献：
  名称：

  Spiro-rifamycin derivatives targeting RNA polymerase

  摘要：

  当前发明的化合物涉及具有抗微生物活性的利福霉素衍生物，包括对耐药微生物的活性。更具体地说，当前发明的化合物涉及一系列表现出强效抗微生物活性的新型螺环利福霉素衍生物。

  公开号：

  US20050277633A1
• 作为产物：
  描述：

  4-氨基-4-氰基-哌啶-1-羧酸叔丁酯 在 镍 吡啶 、 盐酸 、 氨 、 氢气 、 三乙酰氧基硼氢化钠 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 乙酸乙酯 为溶剂， 反应 94.0h， 生成 4-氨基甲基-1-甲基-哌啶-4-基胺
  参考文献：
  名称：

  Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins

  摘要：

  A novel series of spirorifamycins was synthesized and their antibacterial activity evaluated both in vitro and in vivo. This new series of rifamycins shows excellent activity against Staphylococcus aureus that is equivalent to rifabutin. However, some compounds of the series exhibit lower MICs than rifabutin against rifampin-resistant strains of S. aureus. Further, compound 2e exhibits comparable efficacy in vivo in a murine model of S. aureus septicemia model following administration by either oral or parenteral dosing routes.

  DOI：

  10.1016/j.bmcl.2006.12.026

文献信息

• Aza spiro compounds acting on the cholinergic system with muscarinic
  申请人：Israel Institute for Biological Research

  公开号：US05852029A1

  公开（公告）日：1998-12-22

  Compounds useful for treating diseases of the central or peripheral nervous system in mammals have formulae I-XII ##STR1## wherein ring A or A' together with the spiro-carbon atom constitutes a bridged or unbridged ring containing one or two ring nitrogen atoms; and the other symbols have specified values, subject to certain conditions.

  用于治疗哺乳动物中枢神经系统或外周神经系统疾病的化合物具有以下化学式I-XII ##STR1## 其中环A或A'与螺碳原子一起构成一个含有一个或两个环氮原子的桥接环或非桥接环；其他符号具有特定值，受特定条件约束。
• Spiro compounds containing five-membered rings
  申请人：——

  公开号：US05534520A1

  公开（公告）日：1996-07-09

  Compounds useful for treating diseases of the central or peripheral nervous system in mammals have formulae I-XIII: ##STR1## wherein ring A or A' together with the spiro-carbon atom constitutes a bridged or unbridged ring containing one or two ring nitrogen atoms; and the other symbols have specified values, subject to certain conditions.

  用于治疗哺乳动物中枢神经系统或外周神经系统疾病的化合物具有I-XIII式的分子式：##STR1## 其中环A或A'与螺碳原子一起构成一个含有一个或两个环氮原子的桥接环或非桥接环；其他符号具有特定值，受特定条件约束。
• [EN] SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PHOSPHATASE SHP2 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：RELAY THERAPEUTICS INC

  公开号：WO2018057884A1

  公开（公告）日：2018-03-29

  The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments. Other cancers associated with SHP2 deregulation include HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma of the breast, invasive ductal carcinoma of the breast, non-small cell lung cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck (SCCHN), and colon cancer.

  本发明涉及新颖化合物及其药物组合物，以及利用该发明的化合物和组合物抑制SHP2磷酸酶活性的方法。本发明还涉及但不限于抑制肿瘤细胞生长的方法，改善系统性红斑狼疮的发病机制，以及利用本发明的化合物和组合物治疗包括努南综合征、糖尿病、中性粒细胞减少症、神经母细胞瘤、黑色素瘤、儿童白血病、儿童单核细胞白血病、慢性单核细胞白血病、急性髓系白血病等各种其他疾病的方法，单独或与其他治疗方法结合使用。与SHP2失调相关的其他癌症包括HER2阳性乳腺癌、三阴性乳腺癌、乳腺导管癌、浸润性乳腺导管癌、非小细胞肺癌、食管癌、胃癌、头颈部鳞状细胞癌和结肠癌。
• Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring
  申请人：Nishida Hidemitsu

  公开号：US20090076015A1

  公开（公告）日：2009-03-19

  It is intended to provide an anticoagulant that has an extremely excellent FXa inhibitory action and an extremely weak hERG channel inhibitory action and can be orally administered, which is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof.

  该文旨在提供一种极为优异的FXa抑制剂，具有极弱的hERG通道抑制作用，并可口服，该化合物由以下公式(I)所代表，或其药学上可接受的盐。
• FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND
  申请人：Seto Masaki

  公开号：US20100234351A1

  公开（公告）日：2010-09-16

  A compound of the formula: wherein ring A is a 7-membered or 8-membered nitrogen-containing ring optionally further substituted, ring B is an optionally substituted aryl group or an optionally substituted heteroaryl group, X 1 is a group represented by —NR 3 —Y 1 —, —O—, —S—, —SO—, —SO 2 — or —CHR 3 — wherein R 3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R 3 may be bonded to the carbon atom of ring B to form an optionally substituted ring structure, and Y 1 is a bond or an optionally substituted alkylene, R 1 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, the formula shows a single bond or a double bond, when R 2 is —R 2 , R 2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, and when R 2 is ═R 2 , R 2 is an oxo group, an optionally substituted alkylidene group, or an optionally substituted imino group.

  该化合物的化学式为：其中环A是一个7-或8-成员的含氮环，可选择进一步取代，环B是一个可选择取代的芳基或杂芳基，X1是一个由—NR3—Y1—、—O—、—S—、—SO—、—SO2—或—CHR3—表示的基团，其中R3是氢原子或可选择取代的脂肪烃基团，或R3可与环B的碳原子结合形成可选择取代的环结构，Y1是一个键或可选择取代的烷基，R1是氢原子或通过碳原子或硫原子结合的可选择取代的基团，化学式中显示单键或双键，当R2是—R2时，R2是氢原子或通过碳原子结合的可选择取代的基团，氮原子、氧原子或硫原子，当R2是═R2时，R2是一个氧代基团、可选择取代的烷基亚甲基基团或可选择取代的亚胺基团。